Antifibrotic Actions of Serelaxin - New Roles for an Old Player

Trends in Pharmacological Sciences

Volumn 37, Issue 6, 2016, Pages 485-497

  Samuel, Chrishan S ^a   Summers, Roger J ^a   Hewitson, Tim D ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

collagen; fibrosis; relaxin; serelaxin; signal transduction; TGF 1

Indexed keywords

SERELAXIN; TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

AIRWAY REMODELING; ANTIFIBROTIC ACTIVITY; CARDIOMYOPATHY; CAUSAL ATTRIBUTION; CELL DIFFERENTIATION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; FIBROBLAST; FIBROSIS; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOTHERAPY; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; UPREGULATION; ANIMAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; PATHOLOGY; WOUND HEALING;

ANIMALS; DRUG THERAPY, COMBINATION; FIBROSIS; HUMANS; RECOMBINANT PROTEINS; RELAXIN; WOUND HEALING;

EID: 84961230915     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.02.007     Document Type: Review

References (114)

1. T.A. Wynn Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases J. Clin. Invest. 117 2007 524 529
2. D.H. Kang, and et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1 J. Am. Soc. Nephrol. 12 2001 1434 1447
3. S.G. Royce, and et al. Effect of extracellular matrix composition on airway epithelial cell and fibroblast structure: implications for airway remodeling in asthma Ann. Allergy Asthma Immunol. 102 2009 238 246
4. I.A. Darby, and T.D. Hewitson Fibroblast differentiation in wound healing and fibrosis Int. Rev. Cytol. 257 2007 143 179
5. L. Yang, and et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury Nat. Med. 16 2010 535 543
6. S.C. Jones, and et al. High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells Diabetic Med. 16 2000 932 938
7. M. Ruiz-Ortega, and J. Egido Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts Kidney Int. 52 1997 1497 1510
8. M.G. Rohani, and W.C. Parks Matrix remodeling by MMPs during wound repair Matrix Biol. 44-46 2015 113 121
9. O.D. Sherwood Relaxin's physiological roles and other diverse actions Endocr. Rev. 25 2004 205 234
10. R.A. Bathgate, and et al. Relaxin family peptides and their receptors Physiol. Rev. 93 2013 405 480
11. F. Hisaw Experimental relaxation of the pubic ligament of the guinea pig Proc. Soc. Exp. Biol. Med. 23 1926 661 663
12. K.P. Conrad Unveiling the vasodilatory actions and mechanisms of relaxin Hypertension 56 2010 2 9
13. K.P. Conrad Maternal vasodilation in pregnancy: the emerging role of relaxin Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 2011 R267 R275
14. N. Neverova, and J.R. Teerlink Serelaxin: a potential new drug for the treatment of acute heart failure Expert Opin. Investig. Drugs 23 2014 1017 1026
15. J.R. Teerlink, and et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
16. M. Metra, and et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes J. Am. Coll. Cardiol. 61 2013 196 206
17. C.S. Samuel, and T.D. Hewitson Relaxin in cardiovascular and renal disease Kidney Int. 69 2006 1498 1502
18. C.S. Samuel, and et al. Drugs of the future: the hormone relaxin Cell. Mol. Life Sci. 64 2007 1539 1557
19. L.T. Goldsmith, and G. Weiss Relaxin regulates endometrial structure and function in the rhesus monkey Ann. N. Y. Acad. Sci. 1041 2005 110 117
20. M.A. Krajnc-Franken, and et al. Impaired nipple development and parturition in LGR7 knockout mice Mol. Cell. Biol. 24 2004 687 696
21. A.A. Kamat, and et al. Genetic targeting of relaxin and Insl3 receptors in mice Endocrinology 145 2004 4712 4720
22. I. Mookerjee, and et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2 FASEB J. 23 2009 1219 1229
23. C.S. Samuel, and et al. Relaxin family peptide receptor-1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease Endocrinology 150 2009 1495 1502
24. S. Nistri, and et al. Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises Cardiovasc. Hematol. Agents Med. Chem. 5 2007 101 108
25. R.G. Bennett Relaxin and its role in the development and treatment of fibrosis Transl. Res. 154 2009 1 6
26. X.J. Du, and et al. Cardiovascular effects of relaxin: from basic science to clinical therapy Nat. Rev. Cardiol. 7 2010 48 58
27. J.M. Sasser The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease Am. J. Physiol. Regul. Integr. Comp. Physiol. 305 2013 R559 R565
28. V. Cernaro, and et al. Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein Med. Res. Rev. 34 2014 77 105
29. X.J. Du, and et al. Therapeutic effects of serelaxin in acute heart failure Circ. J. 78 2014 542 552
30. S.G. Royce, and et al. Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease Clin. Exp. Allergy 44 2014 1399 1408
31. M.S. Erikson, and E.N. Unemori Relaxin clinical trials in systemic sclerosis G.W. Tregear, Relaxin 2000: Proceedings of the Third International Conference on Relaxin and Related Peptides 2001 Kluwer 373 382
32. J.R. Seibold, and et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial Ann. Intern. Med. 132 2000 871 879
33. D. Khanna, and et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial Arthritis Rheum. 60 2009 1102 1111
34. C.S. Samuel, and et al. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo Endocrinology 145 2004 4125 4133
35. ω-nitro-l-Arginine methyl ester hypertensive rats Hypertension 58 2011 197 204
36. E.N. Unemori, and E.P. Amento Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts J. Biol. Chem. 265 1990 10681 10685
37. E.N. Unemori, and et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo J. Clin. Invest. 98 1996 2739 2745
38. C.S. Samuel, and et al. Relaxin remodels fibrotic healing following myocardial infarction Lab. Invest. 91 2011 675 690
39. M.H. Heeg, and et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway Kidney Int. 68 2005 96 109
40. R.G. Bennett, and et al. Relaxin decreases the severity of established hepatic fibrosis in mice Liver Int. 34 2014 416 426
41. T.D. Hewitson, and et al. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis Endocrinology 151 2010 4938 4948
42. C. Sassoli, and et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling PLoS ONE 8 2013 e63896
43. X. Zhou, and et al. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway Drug Des. Dev. Therap. 9 2015 4599 4611
44. A. Frati, and et al. Role of sphingosine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin Mol. Endocrinol. 29 2015 53 67
45. R. Masterson, and et al. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro Nephrol. Dial. Transplant. 19 2004 544 552
46. N. Haase, and et al. Relaxin does not improve angiotensin II-induced target-organ damage PLoS ONE 9 2014 e93743
47. S.E. Wong, and et al. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes Protein Pept. Lett. 20 2013 1029 1038
48. B.S. Chow, and et al. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS PLoS ONE 7 2012 e42714
49. C.S. Samuel, and et al. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy Endocrinology 149 2008 3286 3293
50. T. Dschietzig, and et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB Circ. Res. 92 2003 32 40
51. T.Y. Ho, and et al. Relaxin-induced matrix metalloproteinase-9 expression is associated with activation of the NF-κB pathway in human THP-1 cells J. Leukoc. Biol. 81 2007 1303 1310
52. E. Masini, and et al. Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway Endocrinology 145 2004 1106 1112
53. S. Nistri, and et al. Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction Pharm. Res. 57 2008 43 48
54. A. Brecht, and et al. Relaxin inhibits early steps in vascular inflammation Regul. Pept. 166 2011 76 82
55. X.L. Moore, and et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes Endocrinology 148 2007 1582 1589
56. T. Dschietzig, and et al. Myocardial relaxin counteracts hypertrophy in hypertensive rats Ann. N. Y. Acad. Sci. 1041 2005 441 443
57. L. Yao, and et al. Relaxin acts on stromal cells to promote epithelial and stromal proliferation and inhibit apoptosis in the mouse cervix and vagina Endocrinology 149 2008 2072 2079
58. T. Yoshida, and et al. Relaxin protects against renal ischemia-reperfusion injury Am. J. Physiol. Renal Physiol. 305 2013 F1169 F1176
59. E.N. Unemori, and et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites Wound Repair Regen. 8 2000 361 370
60. D.R. Stewart Scar prevention and cosmetically enhanced wound healing using relaxin Ann. N. Y. Acad. Sci. 1160 2009 336 341
61. X. Mu, and et al. Relaxin regulates MMP expression and promotes satellite cell mobilization during muscle healing in both young and aged mice Am. J. Pathol. 177 2010 2399 2410
62. J.R. Weinstein, and S. Anderson The aging kidney: physiological changes Adv. Chron. Kid. Dis. 17 2010 302 307
63. A. Biernacka, and N.G. Frangogiannis Aging and cardiac fibrosis Aging Dis. 2 2011 158 173
64. M. Wang, and et al. Central arterial aging and angiotensin II signaling Curr. Hypertens. Rev. 6 2010 266 281
65. M.L. Halls, and et al. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms Mol. Pharmacol. 70 2006 214 226
66. S.Y. Hsu, and et al. The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7 Mol. Endocrinol. 14 2000 1257 1271
67. S.Y. Hsu, and et al. Activation of orphan receptors by the hormone relaxin Science 295 2002 671 674
68. B.T. Nguyen, and et al. Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3′,5′-monophosphate by relaxin Mol. Endocrinol. 17 2003 1075 1084
69. B.T. Nguyen, and C.W. Dessauer Relaxin stimulates protein kinase C zeta translocation: requirement for cyclic adenosine 3′,5′-monophosphate production Mol. Endocrinol. 19 2005 1012 1023
70. αi3 involves the C-terminal Arg752 and localization within membrane Raft microdomains Mol. Pharmacol. 75 2009 415 428
71. M.L. Halls, and et al. Relaxin activates multiple cAMP signaling pathway profiles in different target cells Ann. N.Y. Acad. Sci. 1160 2009 108 111
72. S. Palejwala, and et al. Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment fibroblasts Endocrinology 139 1998 1208 1212
73. T. Dschietzig, and et al. Relaxin improves TNF-Alpha-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling Cardiovasc. Res. 95 2012 97 107
74. M.C. Baccari, and et al. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 2007 R662 R668
75. M.C. Baccari, and et al. Influence of relaxin on the neurally induced relaxant responses of the mouse gastric fundus Biol. Reprod. 71 2004 1325 1329
76. D. Bani, and et al. Relaxin activates the l-Arginine-nitric oxide pathway in vascular smooth muscle cells in culture Hypertension 31 1998 1240 1247
77. K. Alexiou, and et al. Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1 PLoS ONE 8 2013 e75592
78. M. Sarwar, and et al. Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins Br. J. Pharmacol. 172 2015 1005 1019
79. N. Ahmad, and et al. Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-zeta pathways Mol. Cell. Endocrinol. 363 2012 46 61
80. B. Schmierer, and C.S. Hill TGFβ-SMAD signal transduction: molecular specificity and functional flexibility Nat. Rev. Mol. Cell. Biol. 8 2007 970 982
81. Y.H. Fan, and et al. Notch signaling may negatively regulate neonatal rat cardiac fibroblast-myofibroblast transformation Physiol. Res. 60 2011 739 748
82. C.R. Chillakuri, and et al. Notch receptor-ligand binding and activation: insights from molecular studies Semin. Cell Dev. Biol. 23 2012 421 428
83. A. Kern, and et al. Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing G protein-coupled receptor 7) splice variants from human fetal membranes Endocrinology 149 2008 1277 1294
84. A.M. Svendsen, and et al. Cooperative binding of insulin-like peptide 3 to a dimeric relaxin family peptide receptor 2 Endocrinology 149 2008 1113 1120
85. A.M. Svendsen, and et al. Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1 Mol. Cell. Endocrinol. 296 2008 10 17
86. R.C. Kong, and et al. Membrane receptors: structure and function of the relaxin family peptide receptors Mol. Cell. Endocrinol. 320 2010 1 15
87. R.M. Shymko, and et al. Logical analysis of timing-dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways Biochem. J. 326 1997 463 469
88. L.A. Danielson, and K.P. Conrad Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats J. Appl. Physiol. 95 2003 1509 1514
89. D.O. Debrah, and et al. Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response J. Appl. Physiol. 98 2005 1013 1020
90. J.R. Teerlink, and et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding Phase IIb study Lancet 373 2009 1429 1439
91. B.S. Chow, and et al. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis Kidney Int. 86 2014 75 85
92. R.M. Carey Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age Hypertension 45 2005 840 844
93. E.S. Jones, and et al. AT2 receptors: functional relevance in cardiovascular disease Pharmacol. Ther. 120 2008 292 316
94. C.S. Samuel, and et al. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease Hypertension 64 2014 315 322
95. S.G. Royce, and et al. Combination therapy with relaxin and methylprednisolone augments the effects of either treatment alone in inhibiting subepithelial fibrosis in an experimental model of allergic airways disease Clin. Sci. 124 2013 41 51
96. S.G. Royce, and et al. Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma Lab. Invest. 94 2014 1326 1339
97. S.J. Joggerst, and A.K. Hatzopoulos Stem cell therapy for cardiac repair: benefits and barriers Expert Rev. Mol. Med. 11 2009 e20
98. P. Chhabra, and K.L. Brayman The use of stem cells in kidney disease Curr. Opin. Organ Transpl. 14 2009 72 78
99. T. Maron-Gutierrez, and et al. Cell-based therapies for the acute respiratory distress syndrome Curr. Opin. Crit. Care 20 2014 122 131
100. L. Lu, and et al. Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue Biochem. Biophys. Res. Commun. 320 2004 907 913
101. L. Formigli, and et al. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling J. Cell. Mol. Med. 11 2007 1087 1100
102. B.M. Huuskes, and et al. Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy FASEB J. 29 2015 540 553
103. S.G. Royce, and et al. Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease Stem Cell Res. 15 2015 495 505
104. M.A. Hossain, and et al. The minimal active structure of human relaxin-2 J. Biol. Chem. 286 2011 37555 37565
105. J. Xiao, and et al. Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1 Nat. Commun. 4 2013 1953
106. P. Pound, and et al. Where is the evidence that animal research benefits humans? BMJ 328 2004 514 517
107. M.B. Bracken Why animal studies are often poor predictors of human reactions to exposure J. R. Soc. Med. 102 2009 120 122
108. C.S. Samuel, and et al. The relaxin gene knockout mouse: a model of progressive scleroderma J. Invest. Dermatol. 125 2005 692 699
109. S.P. McGorray, and et al. A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability Am. J. Orthod. Dentofacial Orthop. 141 2012 196 203
110. D.R. Stewart, and et al. Use of relaxin in orthodontics Ann. N. Y. Acad. Sci. 1041 2005 379 387
111. Y. Hirate, and et al. Effects of relaxin on relapse and periodontal tissue remodeling after experimental tooth movement in rats Connect. Tissue Res. 53 2012 207 219
112. G. Weiss, and et al. A randomized, double-blind, placebo-controlled trial of relaxin for cervical ripening in post-delivery date pregnancies Ann. N. Y. Acad. Sci. 1160 2009 385 386
113. V.B. Nair, and et al. Synthetic covalently linked dimeric form of H2 relaxin retains native RXFP1 activity and has improved in vitro serum stability Biomed. Res. Int. 2015 2015 731852
114. M.A. Hossain, and et al. The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist Amino Acids 39 2010 409 416